摘要
为探究3.0TDCE-MRI联合血清前列腺游离特异性抗原/总特异性抗原(fPSA/tPSA)对前列腺癌(PCa)的诊断效能,选取疑诊PCa患者168例(PCa组)及前列腺增生患者192例(BPH组),均行3.0TDCE-MRI扫描,计算容积转运常数(Ktrans)、对比剂从血管外细胞外间隙返回血浆的速率常数(Kep)及血管外细胞外间隙容积比例分数(Ve);并用ELISA法检测血清fPSA和tPSA水平,计算fPSA/tPSA。结果显示,PCa组患者的Ktrans、Kep、fPSA、tPSA水平均高于BPH组(P<0.05),而fPSA/tPSA低(P<0.05),Ktrans、Kep与血清fPSA/tPSA呈负相关(P<0.05)。三者联合诊断PCa的AUC为0.961,优于单一指标检测,显著提高了对PCa的诊断效能,更具临床应用价值。
The diagnostic efficacy of 3.0Tdynamic contrast-enhanced magnetic resonance imaging(DCEMRI)combined with serum free prostate specific antigen(fPSA)/total prostate specific antigen(tPSA)in prostate cancer(PCa)was explored.180patients suspected PCa(PCa group)and 180cases of benign prostatic hyperplasia(BPH group)were selected,all subjects were scanned with 3.0TDCE-MRI.The volume transfer constant(Ktrans),the rate constant of the contrast medium returning to the plasma from the extracellular space(Kep)and the volume fraction of the extracellular space(Ve)were calculated.The levels of serum FPSA and TPSA were measured by enzyme-linked immunosorbent assay(ELISA),and the ratio of fPSA/tPSA were calculated.Compared with BPH group,the levels of Ktrans,Kep,fPSA and tPSA in PCa group were significantly higher(P<0.05),while fPSA/tPSA were significantly lower(P<0.05).The levels of Ktrans and Kepof PCa patients were negatively correlated with the levels of serum fPSA/tPSA(P<0.05).The areas under the curve(AUC)of diagnosing PCa by combined detection was 0.961,and it was significantly better than single detection.The levels of Ktrans and Kepof DCE-MRI is correlated with the level of serum fPSA/tPSA,which can significantly improve the diagnostic efficiency of PCa and has more clinical application value.
作者
胡起立
宋黎涛
黄松
HU Qili;SONG Litao;HUANG Song(Imaging Department,The Seventh People’s Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 200137,P.R.China)
出处
《影像科学与光化学》
CAS
2020年第5期871-875,共5页
Imaging Science and Photochemistry
关键词
前列腺癌
3.0T动态增强磁共振成像
前列腺特异性抗原
prostate cancer
3.0T dynamic contrast-enhanced magnetic resonance imaging
prostate specific antigen